The FDA on 6 June 2014 approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, from Biogen IDEC, for use in...
Newly published clinical data demonstrate that people on extended-interval prophylaxis regimens with Eloctate [antihemophilic factor (recombinant), Fc fusion protein] experienced...
Biogen Idec has announced that the FDA has accepted the company's Biologics License Application (BLA) for the marketing approval of...
Orphan Biovitrum announced the final results of ASPIRE the most comprehensive long-term studies of extended half-life factor therapies in haemophilia...
Swedish Orphan Biovitrum AB (publ) (Sobi) and Bioverativ Inc. announce the publication of interim results from a longitudinal study of joint...
Biogen Idec and Swedish Orphan Biovitrum AB (Sobi) released positive top-line results of the Kids A-LONG Phase III clinical study...
Biogen announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company that it expects to launch...
The haemophilia business of Biogen transferred to newly formed Bioverativ Inc.on 1 February 2017 and Bioverativ Inc. now markets Alprolix...
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into...
Swedish Orphan Biovitrum AB announced that Biogen Idec has submitted a Marketing Authorisation Application (MAA) for Elocta (rFVIIIFc) to the...